Table 3.
Association between pelvic radiation and general health-related patient-reported functional outcomes.
| Time | N | Pelvic Radiation, median (quartiles) | No Pelvic Radiation, median (quartiles) | Combined, median (quartiles) | Crude P-valuea | Multivariable adjusted modelb | |
|---|---|---|---|---|---|---|---|
| Pelvic Radiation vs. No Pelvic Radiation | |||||||
| Effect estimate (95% CI) | P-value | ||||||
| SF36 physical functioning score | |||||||
| Baseline | 564 | 85 (50, 95) | 90 (70, 100) | 90 (65, 100) | 0.04 | n/a | |
| 6 month | 572 | 75 (45, 94) | 85 (65, 95) | 85 (60, 95) | 0.003 | 2.44 (−2.31 to 7.18) | 0.31 |
| 1 year | 550 | 85 (50, 95) | 90 (67, 100) | 87 (65, 100) | 0.003 | 2.03 (−2.49 to 6.54) | 0.38 |
| 3 year | 470 | 75 (45, 90) | 85 (60, 95) | 85 (55, 95) | 0.003 | −0.43 (−6.15 to 5.29) | 0.88 |
| 5 year | 415 | 70 (32, 95) | 85 (60, 95) | 85 (55, 95) | 0.006 | −3.74 (−10.92 to 3.43) | 0.31 |
| SF36 emotional well being score | |||||||
| Baseline | 574 | 84 (68, 92) | 88 (72, 92) | 84 (72, 92) | 0.76 | n/a | |
| 6 month | 571 | 84 (75, 92) | 84 (71, 92) | 84 (72, 92) | 0.61 | 3.01 (0.19 to 5.83) | 0.04 |
| 1 year | 548 | 84 (68, 92) | 84 (72, 92) | 84 (72, 92) | 0.90 | 2.30 (−0.31 to 4.91) | 0.08 |
| 3 year | 467 | 84 (76, 92) | 88 (72, 92) | 88 (72, 92) | 0.71 | 1.40 (−2.19 to 4.99) | 0.44 |
| 5 year | 414 | 88 (72, 92) | 88 (72, 92) | 88 (72, 92) | 0.90 | 2.48 (−1.40 to 6.36) | 0.21 |
| SF36 energy and fatigue score | |||||||
| Baseline | 574 | 70 (55, 85) | 75 (55, 85) | 75 (55, 85) | 0.50 | n/a | |
| 6 month | 571 | 65 (50, 80) | 70 (50, 80) | 70 (50, 80) | 0.25 | 2.23 (−1.71 to 6.17) | 0.27 |
| 1 year | 548 | 65 (53, 75) | 70 (50, 80) | 70 (50, 80) | 0.31 | 1.85 (−1.42 to 5.11) | 0.27 |
| 3 year | 467 | 70 (55, 80) | 70 (55, 80) | 70 (55, 80) | 0.28 | 1.80 (−2.11 to 5.70) | 0.37 |
| 5 year | 414 | 65 (52, 80) | 70 (50, 80) | 70 (50, 80) | 0.48 | 3.28 (−1.40 to 7.96) | 0.17 |
Crude P-values are calculated by Wilcoxon test.
All regression models are adjusted for baseline domain score, time since treatment, biopsy Gleason score, PSA at diagnosis (corrected) and propensity scores.